Abbott India Warns Of Laxatives Shortage In Tussle With Goa Regulator

HYDERABAD : Abbott Laboratories’ Indian unit has warned of potential supply shortages of two popular laxative syrups after production was prohibited in India’s Goa state, where drug inspectors have found lapses at a company factory, a letter shows.

Goa, where Abbott has one of its two India plants, asked the company to halt production of Cremaffin and Duphalac syrups last month. The request followed the recall of another Abbott drug which triggered factory inspections by health officials who found contamination risks and sanitisation issues.

The two laxative brands together have estimated annual sales of $70 million in India, healthcare data firm Pharmarack says.

In a letter to Goa’s Directorate of Food and Drugs Administration dated September 18, which is not public and has not previously been reported on, Abbott pushed state regulators to allow it to restart manufacturing the two medicines.

“The two products have a high consumption rate and are highly prescribed,” Abbott said in the letter seen by Reuters. “We are likely to face a supply shortage of these two products,” it warned. Cremaffin, Abbott argued, is a “necessity to support hospitalised patients” while Duphalac is prescribed in serious disorders caused by liver failure.

Abbott in India and the Goa FDA spokesperson did not immediately respond to requests for comment.

India is a major market for Abbott. Its current regulatory challenges in the country began in August with the recall of thousands of bottles of its popular Digene Gel antacid syrup following complaints about its taste and odour.

Abbott has since halted production of Digene but says there is no impact on patient health.

Drug inspectors who visited the Goa facility following the recall flagged issues such as water stagnation in tanks and pipes, saying it could lead to contamination and microbial growth.

They asked the company to fix the problems and the FDA warned it could revoke the manufacturing licence for Digene syrup, Reuters reported earlier this month.

In its latest letter, Abbott told Goa authorities it had taken corrective steps, segregating the manufacturing lines of different drugs and changing its cleaning protocols.

“We are committed to invest and upgrade the manufacturing site,” it said, asking that no action on the licence be taken.

Related Posts

  • Pharma
  • July 24, 2025
  • 180 views
Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

Natco Pharma shares slipped 2.5% to Rs 1,009 apiece on the BSE in Thursday’s trade after the company announced its plan to acquire a 35.75% stake in South Africa-based Adcock…

  • Pharma
  • July 22, 2025
  • 270 views
DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra